Association of IL-8 and ENOS Polymorphisms with Clinical Outcomes in Bevacizumab-treated Breast Cancer Patients: an Exploratory Analysis

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2015 Jul 5

PMID 26141413

Citations 8

Authors

M Di Salvatore

L Lo Giudice

E Rossi

C Santonocito

G Nazzicone

M G Rodriquenz

S Cappuccio

A Inno

P Fuso

A Orlandi

A Strippoli

E Capoluongo

A Astone

A Cassano

C Barone

Affiliations

Soon will be listed here.

Abstract

Background: The role of bevacizumab in metastatic breast cancer is controversial. Identification of predictive biomarkers could help to select patients who really benefit from it. We evaluated the association of angiogenesis-related gene polymorphisms with the treatment outcome of bevacizumab in metastatic breast cancer patients.

Patients And Methods: eNOS-786T/C and -894G/T, IL-8-251T/A genomic polymorphisms were assessed in 31 metastatic breast cancer patients treated with bevacizumab plus chemotherapy in the first-line setting. Testing for association between each polymorphism and treatment outcome was performed.

Results: Patients with IL-8 251 AA genotype showed a significantly lower progression-free survival in each combination comparison: "TT" vs "AA" (13 vs 8 months; p = 0.008); TT vs TA vs AA (13 vs 11 vs 8 months; p = 0.02); TT vs TA +AA (13 vs 11 months; p = 0.01); TT + TA vs AA (12 vs 8 months; p = 0.01) and a lower overall survival when compared with TT +TA genotype (26 vs 51 months, p = 0.04). Patients carrying eNOS 894 TT genotype showed a statistically significant lower progression-free survival than patients with GG genotype (11.5 vs 26.5 months; p = 0.04) with no differences in the overall survival. No association with response rate was found with any of the polymorphisms analyzed.

Conclusion: These findings suggest that IL-8 251T/A and eNOS-894 G/T polymorphisms might have a role in predicting treatment outcome of bevacizumab in metastatic breast cancer. Our results are hypothesis generating and need to be confirmed in larger clinical trials.

Citing Articles

Pan-Cancer Analysis of NOS3 Identifies Its Expression and Clinical Relevance in Gastric Cancer.

Zou D, Li Z, Lv F, Yang Y, Yang C, Song J Front Oncol. 2021; 11:592761.

PMID: 33747912 PMC: 7969995. DOI: 10.3389/fonc.2021.592761.

Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review.

Papachristos A, Sivolapenko G J Pers Med. 2020; 10(3).

PMID: 32759686 PMC: 7563856. DOI: 10.3390/jpm10030079.

and Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer.

Papachristos A, Kemos P, Katsila T, Panoilia E, Patrinos G, Kalofonos H Int J Mol Sci. 2019; 20(22).

PMID: 31752122 PMC: 6888109. DOI: 10.3390/ijms20225791.

An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?.

Liang X, Li H, Coussy F, Callens C, Lerebours F Chin J Cancer Res. 2019; 31(4):586-600.

PMID: 31564802 PMC: 6736652. DOI: 10.21147/j.issn.1000-9604.2019.04.03.

Involvement of endothelial nitric oxide synthase gene variants in the aggressiveness of uterine cervical cancer.

Hung W, Wu T, Ng S, Lee Y, Shen H, Yang S J Cancer. 2019; 10(12):2594-2600.

PMID: 31258766 PMC: 6584934. DOI: 10.7150/jca.33192.

References

Koch A, Polverini P, Kunkel S, Harlow L, DiPietro L, Elner V . Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992; 258(5089):1798-801. DOI: 10.1126/science.1281554. View

Miles D, Chan A, Dirix L, Cortes J, Pivot X, Tomczak P . Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28(20):3239-47. DOI: 10.1200/JCO.2008.21.6457. View

Kopetz S, Hoff P, Morris J, Wolff R, Eng C, Glover K . Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2009; 28(3):453-9. PMC: 2815707. DOI: 10.1200/JCO.2009.24.8252. View

Perlik M, Seremak-Mrozikiewicz A, Barlik M, Kurzawinska G, Krasnik W, Drews K . [Genetic variants of endothelial nitric synthase in gestational hypertension and preeclampsia]. Ginekol Pol. 2013; 83(9):652-9. View

Gyanchandani R, Sano D, Ortega Alves M, Klein J, Knapick B, Oh S . Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol. 2013; 49(8):761-70. DOI: 10.1016/j.oraloncology.2013.03.452. View

Rose S . FDA pulls approval for avastin in breast cancer. Cancer Discov. 2012; 1(7):OF1-2. DOI: 10.1158/2159-8290.CD-ND112311OL-08. View

Kumler I, Christiansen O, Nielsen D . A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev. 2014; 40(8):960-73. DOI: 10.1016/j.ctrv.2014.05.006. View

Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I . Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011; 30:54. PMC: 3120715. DOI: 10.1186/1756-9966-30-54. View

Miles D, Dieras V, Cortes J, Duenne A, Yi J, OShaughnessy J . First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013; 24(11):2773-80. DOI: 10.1093/annonc/mdt276. View

10.

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

11.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

12.

Valachis A, Polyzos N, Patsopoulos N, Georgoulias V, Mavroudis D, Mauri D . Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010; 122(1):1-7. DOI: 10.1007/s10549-009-0727-0. View

13.

Hautamaki A, Kivioja J, Vavuli S, Kakko S, Savolainen E, Savolainen M . Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. Retina. 2013; 33(9):1815-27. DOI: 10.1097/IAE.0b013e318285cf92. View

14.

Abajo A, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Rodriguez J . Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer. 2012; 107(2):287-90. PMC: 3394977. DOI: 10.1038/bjc.2012.242. View

15.

Eechoute K, van der Veldt A, Oosting S, Kappers M, Wessels J, Gelderblom H . Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012; 92(4):503-10. DOI: 10.1038/clpt.2012.136. View

16.

Smith I, Pierga J, Biganzoli L, Cortes-Funes H, Thomssen C, Pivot X . First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2010; 22(3):595-602. DOI: 10.1093/annonc/mdq430. View

17.

OShaughnessy J, Brufsky A . RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2008; 8(4):370-3. DOI: 10.3816/CBC.2008.n.045. View

18.

Miles D . Bevacizumab in breast cancer: fundamental questions remain. Lancet Oncol. 2013; 14(2):99-101. DOI: 10.1016/S1470-2045(13)70012-3. View

19.

Schneider B, Gray R, Radovich M, Shen F, Vance G, Li L . Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013; 19(5):1281-9. PMC: 3594423. DOI: 10.1158/1078-0432.CCR-12-3029. View

20.

Hull J, Thomson A, Kwiatkowski D . Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax. 2000; 55(12):1023-7. PMC: 1745668. DOI: 10.1136/thorax.55.12.1023. View